Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases.
Introduction
Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases (i.e., vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), Flt3, and c-KIT). The anti-tumor effect of sorafenib is thought to be mediated through its inhibition of the RAS-Raf-Erk pathway 1 , which is involved in cell proliferation, as well as its inhibition of VEGFR and PDGFR, which play a role in angiogenesis 2, 3 .
Sorafenib has been effective at treating patients with renal cell carcinoma (RCC) 4 and hepatocellular carcinoma (HCC) 5 .
Ovarian clear cell carcinoma (OCCC) has a specific gene expression profile 6 , and is a chemoresistant histological subtype of ovarian cancer. OCCC is represented by cells with clear cytoplasm that resemble those observed in RCC. Using a microarray database, we previously reported that the gene expression profile of OCCC was similar to that of RCC, and we showed good effects of sorafenib in a mouse model of OCCC 7 .
The effects of sorafenib against human OCCC are unknown. Therefore, we attempted to use sorafenib to treat two patients with recurrent chemoresistant OCCC. This is the first case report to evaluate sorafenib efficacy against OCCC.
Case Description
We used sorafenib monotherapy (400 mg/day, orally) in two patients with recurrent and chemoresistant OCCC after written informed consents were obtained. The efficacy of the treatment was judged based on progression-free survival for at least six months (RECIST 1.1). These clinical studies had been approved by the institutional review board (IRB) of Kyoto University in advanced. By eight years after the primary surgery, the mediastinal, axillary and neck lymph nodes had increased by degrees.
The patient then was prescribed 400 mg/day of sorafenib for five months.
The sizes of the neck lymph nodes were not significantly different before and after treatment (Figs 3a, b) , which was judged to indicate 'stable disease' for six months. The serum levels of CA125 were 193.2 U/ml and 203.5 U/ml before and after the treatment, respectively (Fig. 4) . The only side effect was mild hand-foot syndrome (grade1).
After sorafenib therapy, the metastatic neck lymph nodes increased suddenly. External irradiation against the bilateral neck regions (60 Gy), the right axillary lymph nodes (28 Gy) and the para-aortic lymph nodes (30 Gy) was performed. However, airway narrowing occurred due to swelling of the neck lymph nodes. After a tracheotomy, the patient died due to ileus and bleeding from the bronchi. This was approximately nine years after the primary surgery.
Discussion
Epithelial ovarian carcinoma is histologically divided into serous (OS), endometrioid (OE), mucinous (OM) and OCCC subtypes. OM and OCCC are both commonly considered to be chemoresistant tumors. OCCCs are rare tumors in Europe and the United States 8 ; however, they occur often in Japan (20%) 9 . Therefore, we have searched for agents that are effective against OCCC.
We previously showed that the gene expression profile of OCCC was similar to that of RCC using microarray datasets of ovarian cancer cell lines and human cancer tissues specimens 7 . We also showed the genes exclusively expressed in OCCC, termed OCCC signature, contained a large gene network consisting of 66 genes, including hepatocyte nuclear factor 1-beta (HNF1B) and hypoxia inducible factor 1-alpha subunit (HIF1A) 6 .
HNF1B is functionally associated with renal morphogenesis 10 . In addition, pathway analysis indicated the Ras-Raf-Erk signaling is activated in OCCC 7 .
RCC is also a chemoresistant tumor. Sorafenib has recently been approved for RCC, and is considered to be a reasonable molecular targeting drug against RCC. All sporadic and inherited forms of RCC are associated with mutations in the VHL gene and loss of heterozygosity 11, 12 , resulting in the stabilization of the HIF1A protein. HIF1A activates multiple growth factor receptors, such as the EGFR, PDGFR and VEGFR. In addition,
increased Ras pathway signaling is observed in RCC 13 . The anti-tumor effect of sorafenib is thought to be mediated through its inhibition of the RAS-Raf-Erk pathway as well as its inhibition of VEGFR and PDGFR [1] [2] [3] .
We showed that orally administered sorafenib significantly inhibited the growth of RMG-2, a representative OCCC cell line, in nude mice 7 . We therefore attempted to use sorafenib for human patients with recurrent chemoresistant OCCC.
Both of our patients with OCCC were judged to have 'stable disease' following the use of sorafenib monotherapy and exhibited progression-free survival of at least six months. This suggests that sorafenib is an effective agent against recurrent OCCC. Our two patients were able to continue sorafenib monotherapy (400 mg/day) without severe side effects. Both patients had mild/moderate hand-foot syndrome (grades 1 and 2) and one also had hypertension (grade 2). In fact, we used sorafenib monotherapy for another patient with OCCC for two months. However, therapy had to be stopped due to Trousseau syndrome. The disease was stable for two months, and the side effect was a mild rash (grade 1).
Recently, the Gynecologic Oncology Group reported that sorafenib had modest antitumor activity, but did not provide a sufficient effect as a treatment for ovarian cancer 14 . Fifty-nine patients with measurable diseases of recurrent ovarian or peritoneal carcinoma were enrolled in this study, but only 14 patients (24%) survived progression-free for six months.
This study was conducted mostly for the OS subtype (90%) ，whereas only one patient (1.4%) had OCCC. Interestingly, in this study, one of the two patients with partial responses was the patient with OCCC. The data from this study appear to support our result suggesting promising effects of sorafenib against OCCC.
The conventional dose of sorafenib is 800 mg/day 14, 15 . For case 1, we initiated sorafenib treatment with a dose of 800 mg/day, but the dose was soon decreased to 400 mg/day due to hand-foot skin reaction. In a clinical trial conducted for Japanese patients with RCC, dose reduction or therapy interruption due to adverse events was required for as many as 81% of the patients, which is a much higher percentage than for American or European patients 16 . We therefore initiated treatment with a dose of 400 mg/day for case 2. Regardless of the decreased dose, sorafenib showed significant anti-tumor activity in the two OCCC patients.
We believe that sorafenib is an effective agent against OCCC. Given the chemoresistant nature of this tumor, this drug appears to be very valuable.
A clinical trial should be performed using sorafenib to treat OCCC. In addition, a further combination regimen 17 using sorafenib may be more effective against OCCC. Clinical course of the patient and changes in CA125 (case1).
Sorafenib monotherapy suppressed CA125 elevation. 
